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The Impact of Including Costs and Outcomes
of Dementia in a Health Economic Model to
Evaluate Lifestyle Interventions to Prevent
Diabetes and Cardiovascular Disease
Penny Breeze , Chloe Thomas, Praveen Thokala, Louise Lafortune,
Carol Brayne, and Alan Brennan
Objectives. Economic evaluations of lifestyle interventions, which aim to prevent diabetes/cardiovascular disease
(CVD), have not included dementia. Lifestyle interventions decrease dementia risk and extend life expectancy, lead-
ing to competing effects on health care costs. We aim to demonstrate the feasibility of including dementia in a public
health cost-effectiveness analysis and quantify the overall impacts accounting for these competing effects. Methods.
The School for Public Health Research (SPHR) diabetes prevention model describes individuals’ risk of type 2 dia-
betes, microvascular outcomes, CVD, congestive heart failure, cancer, osteoarthritis, depression, and mortality in
England. In version 3.1, we adapted the model to include dementia using published data from primary care data-
bases, health surveys, and trials of dementia to describe dementia incidence, diagnosis, and disease progression. We
estimate the impact of dementia on lifetime costs and quality-adjusted life years (QALYs) gained of the National
Health Service diabetes prevention program (NHS DPP) from an NHS/personal social services perspective with 3
scenarios: 1) no dementia, 2) dementia only, and 3) reduced dementia risk. Subgroup, parameter, and probabilistic
sensitivity analyses were conducted. Results. The lifetime cost savings of the NHS DPP per patient were £145 in the
no-dementia scenario, £121 in the dementia-only scenario, and £167 in the reduced dementia risk scenario. The
QALY gains increased by 0.0006 in dementia only and 0.0134 in reduced dementia risk. Dementia did not alter the
recommendation that the NHS/DPP is cost-effective. Conclusions. Including dementia into a model of lifestyle inter-
ventions was feasible but did not change policy recommendations or modify health economic outcomes. The impact
on health economic outcomes was largest where a direct impact on dementia incidence was assumed, particularly in
elderly populations.
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Hypertension, hypercholesterolemia, smoking, diabetes,
obesity, physical inactivity, and stroke are known to be
risk factors for dementia.1–3 Improvements in midlife
obesity, hypertension, and dyslipidemia are believed to
reduce the incidence of dementia.4 Delaying dementia
onset by 1 year could dramatically affect its prevalence,
reducing disease frequency by approximately 10%.5
Although recent trials for dementia prevention through
vascular risk and lifestyle intervention have not identified
a reduction in dementia incidence or cognitive decline in
the intent-to-treat (ITT) population, subgroup analyses
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indicate that lifestyle interventions can have small benefi-
cial effects.6,7
Diabetes prevention programs (DPPs) are effective in
reducing the incidence of diabetes and lowering the risk
of cardiovascular diseases.8–10 The School for Public
Health Research (SPHR) diabetes prevention model esti-
mated that the National Health Service (NHS) DPP in
individuals with HbA1c 42 mmol/L would generate life
year gains, be cost-effective, and offer good return on
investment for the NHS.11 However, this analysis, like
other economic evaluations for obesity and diabetes pre-
vention,12 does not include dementia as a health condi-
tion. Given the nature of the NHS DPP, with its focus
on dietary advice, physical activity, and weight loss, it is
conceivable that these interventions, closely similar to
those of dementia risk reduction, could improve brain
health.
Including dementia adds additional complexity to dia-
betes and the cardiovascular disease risk model. However,
excluding dementia from economic evaluations of lifestyle
interventions to targeting diabetes and cardiovascular dis-
ease may not account for health care costs in added years
of life gained from the intervention and underestimating
the intervention cost savings and quality-adjusted life year
(QALY) gains from reduced dementia diagnoses. This
could lead to an inefficient allocation of resources. It is not
known what impact these competing factors will have on
the economic case for implementing the program and
whether the net effect will improve, or worsen, the cost-
effectiveness of lifestyle interventions.
The aim of this study is 3-fold. First, we describe an
adaptation to an existing model to evaluate diabetes and
cardiovascular disease (CVD) prevention lifestyle inter-
ventions and incorporate dementia as an explicit out-
come. We describe the methods and sources of data used
to estimate dementia incidence, diagnosis, disease pro-
gression, costs, and health state utilities. Second, the
analysis seeks to investigate the impact on cost-effectiveness
outcomes of including dementia by using the NHS DPP
as an illustration of how costs and prevention of demen-
tia affect the cost-effectiveness of the intervention.
Third, we identify when the inclusion of dementia in a
public health model for lifestyle interventions will have
the greatest impact on cost-effectiveness outcomes.
Methods
We developed 3 primary analyses for this study compar-
ing NHS DPP v. no implementation. First, the NHS
DPP intervention and control arms were simulated
without dementia as a health outcome, using the origi-
nal model structure with updated metabolic trajec-
tories, costs, and study population. This analysis is
labeled as no dementia. Second, the NHS DPP inter-
vention and control arms were simulated with dementia
as a health outcome incurring costs, utility decrements,
and mortality impacts. Dementia incidence was reduced
because fewer individuals develop diabetes and stroke,
but we assumed no direct intervention effect. This anal-
ysis is labeled as dementia only. Third, the NHS DPP
intervention was simulated with dementia as a health
outcome and a relative risk reduction in dementia risk
derived from changes in metabolic risk factors and the
Cardiovascular Risk Factors, Aging, and Incidence of
Dementia (CAIDE) risk modification for lifestyle fac-
tors. This analysis is labeled as reduced dementia risk.
Original Diabetes Prevention Model Structure
The SPHR diabetes prevention model was developed to
forecast long-term health and health care costs of inter-
ventions targeting diabetes prevention in England.13,14
The model is an individual patient simulation model and
based on the evolution of personalized trajectories for
metabolic factors, including body mass index (BMI), sys-
tolic blood pressure (SBP), cholesterol, and measures of
blood glucose (including HbA1c) based on analyses of
the Whitehall II cohort.15
An individual-level simulation enables multiple risk
factors to affect a wider range of health outcomes and
events occurring at various times and stages of life.
The model runs in annual cycles (see schematic in
Suppl. Figure S1). For each person, their BMI, choles-
terol, SBP, and HbA1c progress from year to year. Every
year in the model, an individual may visit their general
practitioner (GP) or undergo a health check and be diag-
nosed with and treated for hypertension, high cardiovas-
cular risk, diabetes, microvascular complications of
diabetes, CVD, congestive heart failure, osteoarthritis,
depression, and breast or colon cancer. Mortality can
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occur in any cycle, and individuals are at increased risk of
death with a history of cardiovascular disease, cancer, or
diabetes. Baseline health-related quality of life (HRQoL)
for each individual in the model accounts for variation in
the population. In the simulation, HRQoL deteriorates
over time with age and medical complications. Each con-
dition is associated with a utility decrement and a health
and social care cost based on published evidence. The
analysis includes the NHS costs and the social care costs.
The model estimates the lifetime costs of interventions
and care, together with the lifetime QALYs, in a 2-arm
comparison of NHS DPP v. no implementation. Costs
and QALYs were discounted at a rate 3.5% per annum.
A full detailed description of the methodology, evi-
dence, data, and assumptions used in the original model
can be found in sections 6 to 10 of the supplementary
material to this article. The validation of key dementia
outcomes is also described in section 13 of the supple-
mentary material. Validation analyses to test the model’s
performance in simulating metabolic trajectories, dia-
betes incidence, cardiovascular disease incidence, blind-
ness, amputation, foot ulcer, and renal failure are
described in the supplementary material published with
the original article.13 The analysis was conducted in ver-
sion 3.1 of the SPHR diabetes prevention model using R
version 3.6.1.
Updated Metabolic Trajectories in Older Age
To account for changes to metabolic trajectories in older
ages, we developed new analyses of the English Longi-
tudinal Study of Ageing16 to predict changes in BMI,
SBP, cholesterol, and measures of blood glucose (includ-
ing HbA1c) using analyses for individuals aged 60 years
or over (see section 6 of the supplementary material).
Study Population
The SPHR diabetes prevention model was updated with
baseline population from the Health Survey for England
(HSE).17 HSE 2014 was chosen to inform the baseline
population to describe correlations between demo-
graphics, metabolic baseline risk factors, and HRQoL
from a representative sample of the English population.
Individuals meeting 3 eligibility criteria for the NHS
DPP (HbA1c 6%–6.4%, aged 16, no existing diabetes
diagnosis) were selected from the HSE 2014 population.
It was assumed that eligible individuals have already
been identified as meeting eligibility criteria, and we do
not incorporate any costs or utility change associated
with identification or referral to the scheme, in line with
previous analyses. The characteristics of the eligible pop-
ulation are shown in Table 1.
Intervention Metabolic Effects
The NHS DPP consists of an intensive lifestyle manage-
ment program aimed at those at high risk of diabetes due
to impaired glucose regulation (IGR). IGR is defined as
HbA1c 6% to 6.4% (42–47 mmol/mol) or fasting plasma
glucose of 5.5 to 6.9 mmol/L. Evidence for the effective-
ness of the program came from a Public Health England
(PHE) commissioned evidence review and meta-analysis
of pragmatic diabetes prevention interventions, which
was used in previous work to evaluate the NHS DPP18
(see Table 1). The average cost of the DPP intervention
from the PHE impact assessment of £270 per participant
was used.11
The SPHR diabetes prevention model implements
intervention effects through instantaneous alterations in
metabolic trajectories in year 1 of the simulation, as most
of the evidence is based on effects observed at intervals of
6 months/1 year. Beyond that, we assume that the gap
between the intervention and control arm narrows over
time. It was assumed that individuals return to the BMI/
SBP/HbA1c/cholesterol level that they would have been
without intervention after 5 years, consistent with the
previous modeling assumptions for the National Institute
for Care Excellence (NICE) guidelines for diabetes pre-
vention (PH38)19 (Table 2).
In the control arm of the simulation, the eligible popu-
lation did not receive any intervention to prevent diabetes
and did not incur any additional costs beyond the usual
monitoring and care described within the model.
Adapting the Model to Include Dementia
The simulation was adapted to estimate the incidence of
dementia for the population. We do not distinguish
between dementia subtypes (e.g., Alzheimer, vascular)
because categorizing dementia types was not indicated
for an analysis that is aiming to estimate the burden of
dementia in the population. An individual’s risk of
dementia can be calculated from age 60 onward using 2
published risk scores for dementia diagnosis.2 The risk
models were estimated from a sample of 930,395 people
who were followed for 5 years in The Health Improvement
Network (THIN) primary care data set, which charac-
terizes current patterns of routine diagnosis.2 In the
simulation, the risk scores are used to estimate the prob-
ability of dementia diagnosis conditional on the individ-
ual’s simulated risk factors such as socioeconomic
Breeze et al. 3
Table 1 Key Model Inputs and Parameters
Baseline Characteristics of Eligible Population from HSE17
Characteristic Number Percentage
Male 1042 44.7%
Nonwhite 249 10.7%
Current smoker 446 19.1%
Past smoker 684 29.4%
Hypertension 615 26.4%
Mean SD Median
Age (years) 57.1 17.6 59
BMI (kg/m2) 28.5 5.4 28
Systolic blood pressure (mm Hg) 129.9 17.7 130
Total cholesterol (mmol/L) 5.2 1.1 5.2
HDL cholesterol (mmol/L) 1.5 0.47 1.5
HbA1c (%) 6.2 0.15 6.2
Mean Effectiveness Evidence from PHE Evidence Review18
Mean SE Source
BMI (kg/m2) –1.47 0.156 (18)
HbA1c (%) –0.20 0.043 (18)
Systolic blood pressure (mm Hg) –6.57 0.923 (18)
Total cholesterol (mmol/L) –0.28 0.028 (18)
Intervention cost £270 (11)
Duration of effect 5 years (11)
Key Dementia Incidence Parameters
THIN (60–80 years) hazard ratio BMI 0.940 0.0038 (2)
THIN (60–80 years) hazard ratio BMI2 1.003 0.0003 (2)
THIN (60–80 years) hazard ratio antihypertensives 0.876 0.0296 (2)
THIN (60–80 years) hazard ratio stroke 1.781 0.0394 (2)
THIN (60–80 years) hazard ratio diabetes 1.332 0.0417 (2)
CAIDE odds ratio obese 2.296 0.3034 (4)
CAIDE odds ratio hypertension 2.206 0.3238 (4)
CAIDE odds ratio hyperlipidemia 1.879 0.3161 (4)
Dementia Progression Annual Rate of MMSE Change
Intercept –5.4663 0.9836 (21)
PM1 [min(PrevMMSE, 9)] –0.4299 0.0597 (21)
PM2 [max[0, min(PrevMMSE, –9, 9)]] –0.0042 0.0410 (21)
PM3 [max[0, min(PrevMMSE, –18, 12)]] 0.1415 0.0487 (21)
Age at baseline 0.0747 0.0127 (21)
Previous rate of MMSE change –0.0791 0.0317 (21)
Dementia Mortality Parameters
Hazard ratio dementia mortality 60–85 years 4.54 0.1276 (26)
Hazard ratio dementia mortality 75+years 2.77 0.0784 (26)
Dementia Costs
Health care cost mild dementia (MMSE 21–26) £3103 Assumed 10% (23)
Health care cost moderate dementia (MMSE 10–20) £8293 Assumed 10% (23)
Health care cost severe dementia (MMSE 0–9) £9841 Assumed 10% (23)
Social care cost mild dementia (MMSE 21–26) £5674 Assumed 10% (23)
Social care cost moderate dementia (MMSE 10–20) £22703 Assumed 10% (23)
Social care cost severe dementia (MMSE 0–9) £23466 Assumed 10% (23)
(continued)
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status, smoking, gender, age, BMI, systolic blood pres-
sure, lipids, antihypertensive, diabetes, depression, and
history of stroke. Other risk factors, such as anxiety and
nonsteroidal anti-inflammatory drugs (NSAIDs), were
added to the simulated individual’s profile information
in line with prevalence statistics reported in the THIN
Table 1 (continued)
Baseline Characteristics of Eligible Population from HSE17
Characteristic Number Percentage
Dementia Utilities
Utility decrement MMSE 21–25 0.93 Assumed 10% (24)
Utility decrement MMSE 15–20 0.725 Assumed 10% (24)
Utility decrement MMSE 10–14 0.710 Assumed 10% (24)
Utility decrement MMSE 0–9 0.478 Assumed 10% (24)
BMI, body mass index; CAIDE, Cardiovascular Risk Factors, Aging, and Incidence of Dementia; HDL, high-density lipoprotein; HSE, Health
Survey for England; MMSE, Mini Mental State Examination; PHE, Public Health England; PM, Previous MMSE; THIN, The Health
Improvement Network.
Table 2 Comparison of Results with and without Dementia Included: Lifetime Cost Effectiveness of NHS DPP v. No
Implementation of NHS DPP
No Dementia Dementia Only Reduced Dementia Risk
Absolute Results No DPP DPP No DPP DPP No DPP DPP
Net benefit (£20,000 willingness to pay) 186,525 186,525 180,904 181,771 180,904 182,074
Health and social care cost (per person) 26,870 26,725 30,134 30,013 30,134 29,967
Health care cost (per person) 25,032 24,909 25,604 25,493 25,604 25,511
Social care cost (per person) 1838 1816 4530 4520 4530 4455
Dementia cost (per person) NA NA 1172 1177 1172 1146
Cardiovascular cost (per person) 6550 6453 6361 6266 6361 6289
QALYs (per person) 10.67 10.71 10.55 10.59 10.55 10.60
Life years (per 1000 people) 24.17 24.24 23.74 23.80 23.74 23.84
Diabetes diagnoses (per 1000 people) 663 651 657 646 657 647
CVD events (per 1000 people) 456 453 446 443 446 445
Dementia diagnosis (per 1000 people) 231 232 242 243 242 238
Targeting Strategy (Incremental Results v. Do Nothing)
Incremental Results for DPP v. No DPP
No
Dementia
Dementia
Only
Difference from
No Dementia
Reduced
Dementia Risk
Difference from
No Dementia
Incremental net benefit (£20,000 willingness to pay) £1000 £987 –£13 £1290 £291
Incremental health and social care cost (per person) –£145 –£121 £24 –£167 –£22
Incremental health care cost (per person) –£123 –£111 £12 –£93 £30
Incremental social care cost (per person) –£23 –£10 £13 –£75 –£52
Incremental dementia cost (per person) 0 £5 £5 –£26 –£26
Incremental cardiovascular cost (per person) –£97 –£95 £2 –£72 £25
Incremental QALYs (per person) 0.0427 0.0433 0.0006 0.0562 0.0134
Incremental life years (per person) 0.0635 0.0665 0.0030 0.1003 0.0368
Incremental diabetes diagnoses (per 1000 people) –11 –11 0 –10 1
Incremental CVD events (per 1000 people) –3 –3 0 –1 1
Incremental dementia diagnosis (per 1000 people) 0 1 1 –4 –4
CVD, cardiovascular disease; DPP, diabetes prevention program; NHS, National Health Service; QALY, quality-adjusted life year.
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data. In each model cycle, the THIN risk scores gener-
ated a probability of dementia diagnosis for eligible
individuals. The probabilities were sampled at random
to determine dementia diagnosis. Severity and progres-
sion of dementia are modeled using the Mini Mental
State Examination (MMSE). To generate heterogeneity
in cognitive function at dementia diagnosis, a Gamma
distribution was fitted to match summary data from the
population-based Cognitive Function and Ageing Study
data.20 The data were fitted to summary statistics, so
cognitive function is not linked to age, sex, or health sta-
tus. Cognitive decline is characterized by changes in
MMSE score over time from a statistical analysis of the
Consortium to Establish a Registry for Alzheimer’s
Disease, developed for a pharmacoeconomic model for
donepezil.21,22
Dementia diagnosis costs, ongoing health care, social
care costs associated with dementia, and level of cogni-
tive impairment were taken from a dementia costing
study. This study provides a synthesis of best available
evidence from trials and observational studies to estimate
the current cost of dementia by severity level.23 HRQoL
scores were attributed to cognitive impairment based on
a study of utilities in Alzheimer disease,24 which was used
in the most recent NICE Health Technology Assessment
for Alzheimer disease,25 and no more recent studies were
identified. The risk of all-cause mortality following
dementia is increased based on estimates from 2 cohort
studies,26 which included 2566 persons over 8 years. The
hazard ratios were applied in the model to all-cause mor-
tality to describe mortality at younger ages (60–84) and
older ages (85+). Full details of the dementia modeling
assumptions and parameters can be found in section 7 of
the supplementary material. A summary of key para-
meters is presented in Table 1.
Intervention Effects on Dementia Incidence
In the no-dementia scenario, the intervention has no
effect on dementia incidence. In the dementia-only sce-
nario, dementia incidence is modified only through indi-
rect reductions in diabetes and stroke incidence. In the
reduced dementia risk scenario, changes in BMI, blood
pressure, and cholesterol are assumed to reduce the inci-
dence of dementia for 20 years after initiating the inter-
vention based on evidence from the CAIDE Dementia
Risk Score.4
The CAIDE risk score predicts the risk of dementia
based on vascular, behavioral, and demographic risk fac-
tors during a 20-year follow-up of 1409 individuals. We
estimate a relative risk reduction for the intervention
based on the observed changes in BMI, systolic blood
pressure, and cholesterol and the odds ratios from the
CAIDE risk score. The relative risk is calculated based
on the magnitude and duration of changes in metabolic
risk factors to reflect the temporary intervention effect
on dementia risk. This relative risk is applied to the prob-
ability of dementia estimated by the THIN risk scores in
the model. Full details of how the relative risk of demen-
tia associated with the intervention has been calculated
can be found in section 7 of the supplementary material.
Estimating Costs and QALYs
Costs were estimated from an NHS and personal social
services (PSS) perspective in 2016–2017 UK pounds.
Table 3 Incremental and Net Benefit Results for Subgroup Analyses
Incremental Costs Incremental QALYs Net Benefit
Characteristic
No
Dementia
Dementia
Only
Reduced
Dementia
Risk
No
Dementia
Dementia
Only
Reduced
Dementia
Risk
No
Dementia
Dementia
Only
Reduced
Dementia
Risk
Base case analysis –£145 –£121 –£167 0.0427 0.0433 0.0562 £1000 £987 £1290
Target age 40–50 –£296 –£282 –£286 0.0354 0.0332 0.0370 £1004 £947 £1026
Target age 50–60 –£271 –£267 –£273 0.0414 0.0406 0.0483 £1099 £1079 £1239
Target age 60–70 –£174 £–131 –£164 0.0613 0.0612 0.081 £1399 £1354 £1783
Target age 70–80 –£2 £47 –£67 0.0581 0.0581 0.089 £1165 £1116 £1842
High risk of diabetes
(HbA1c 6.2%–6.4%)
–£239 –£214 –£255 0.0516 0.0513 0.0629 £1271 £1240 £1513
Low risk of diabetes
(HbA1c 6.0%–6.1%)
–£34 –£39 –£84 0.0411 0.0350 0.0473 £856 £738 £1030
QALY, quality-adjusted life year.
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Health care and social care costs were assigned to all the
health outcomes simulated in the model to estimate an
overall cost for each individual in the model. Costs accu-
mulate additively in the model, so there is a risk of dou-
ble counting some aspects of health care resource use.
However, the extent of overlapping costs is likely to be
small given that the costs of diabetes describe mainly
treatment costs and glucose monitoring. CVD is mostly
driven by the cost of acute hospitalization and outpatient
visits, while the costs of cancer are driven by treatment
costs, renal failure by the cost of dialysis, and osteoar-
thritis from the costs of replacement surgery. In contrast,
the costs of dementia are driven by residential and com-
munity services.
At baseline, EQ-5D scores were extracted from the
HSE data set to describe an individual’s HRQoL, and a
utility decrement for age was applied to the baseline EQ-
5D each year.27 CVD, cancer, microvascular disease,
osteoarthritis, cognitive impairment (MMSE score), and
depression were associated with a utility factor decrement
that was multiplied by the individual’s utility, adjusted
for age. HRQoL decrements were applied multiplicatively
to avoid double counting of HRQoL loss due to multi-
morbidity.28 Details of how costs and utilities were esti-
mated and how they were used in the model are detailed
in sections 8 to 10 of the supplementary material.
Outcomes
Lifetime costs and QALYs were discounted at 3.5% per
annum. We estimated the overall incremental monetary
benefit of the interventions per person by assuming a
willingness to pay (l) of £20,000 per QALY. Net benefit
values above zero are cost-effective, with higher values
being more cost-effective than lower values.
IncrementalNet Benefit= l inc:QALYð Þ  (inc:Cost)
The model also allowed us to estimate the incremental
change in diabetes, CVD, and dementia diagnoses.
Scenario Analysis
The NHS DPP v. no implementation is evaluated in 3
main scenarios. The no-dementia scenario provides a
baseline model in which the model has been updated
from previous versions but where dementia is not modeled.
The dementia-only scenario includes the THIN dementia
risk model, dementia diagnosis, MMSE progression, mor-
tality risk, costs, and health-related quality of life decre-
ments as described earlier. The reduced dementia risk
model includes all aspects of the dementia-only model,
plus a dementia risk reduction associated with modifi-
cation of lifestyle risk factors using the coefficients
from the CAIDE risk score.
Additional stratified analyses investigated the impact
of population characteristics on the net benefit across
subgroups of the population. This analysis aimed to
investigate whether there were particular populations
where including dementia would have a greater impact
on cost-effectiveness outcomes. For these additional
analyses, the cohort was stratified by age and diabetes
risk (HbA1c 6.0%–6.1%, HbA1c 6.2%–6.4%).
Sensitivity Analyses
Several sensitivity analyses were conducted to explore the
impact of dementia parameters on the health economic
outcomes. A full list of sensitivity analyses conducted can
be found in the supplementary material. To investigate
parameter uncertainty, 5000 probabilistic sensitivity anal-
ysis (PSA) samples were run for individuals in the eligible
population.
Results
The absolute costs and health benefits for all scenarios
are reported in Table 2. Including dementia as an out-
come increases the total lifetime health and social care
costs in the dementia-only and reduced dementia risk sce-
narios. Incorporating dementia diagnosis and dementia-
related mortality leads to an overall reduction in number
of diabetes diagnoses and cardiovascular events and
fewer lifetime QALYs gained.
The incremental costs and health benefits for the DPP
compared with a do-nothing intervention are reported in
Table 2. The dementia-only analysis shows that including
dementia, with no direct intervention effect, has a modest
effect on the incremental analysis. The additional costs of
extending life expectancy outweigh the benefits of
reduced dementia incidence via stroke and diabetes. The
intervention remains cost saving, but with less cost sav-
ings across health and social care and fewer QALY gains.
In the reduced dementia risk scenario, where the CAIDE
risk score is used to estimate a direct intervention effect
on the incidence of dementia, the overall net benefit is
greater than the no-dementia scenario. Additional cost
savings are observed in social care and dementia costs,
but these cost savings are mitigated by less cost savings
related to cardiovascular events.
Figure 1 illustrates how incremental costs are recouped
in the short term. In the no-dementia scenario, it is esti-
mated to take around 12 years for the NHS DPP to
become cost saving. The dementia-only scenario increased
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the time slightly to deliver cost saving but not above 12
years. In the reduced dementia risk scenario, where the
intervention is assumed to have a direct effect on demen-
tia risk using the CAIDE risk score, the time to cost sav-
ings is reduced to 10 years.
Stratified analyses explored the impact of population
age and diabetes risk on the incremental costs and
QALYs (Table 3). In the dementia-only scenario, the net
benefit decreased in all subpopulations, but the decrease
was larger in a younger cohort and lower diabetes risk.
In the reduced dementia risk scenario, there is a clear
trend to increasing net benefit in older populations.
The sensitivity analysis found a reasonable degree of
stability in the model outcomes to dementia-related para-
meters (Suppl. Table S53). The dementia-related para-
meters, including dementia incidence, associations between
diabetes, stroke and dementia, dementia costs, utilities,
mortality risk, and MMSE score progression, did not sub-
stantially affect health economic outcomes. The relative
risk parameter based on the CAIDE risk score had a nota-
ble impact on the net benefit in the reduced dementia risk
scenario. The probabilistic sensitivity analysis indicates that
there is a 98% probability that the DPP is cost-effective
with dementia as a health outcome across all scenarios
(Figure 2).
Discussion
The study shows that explicitly modeling dementia as a
health outcome in the dementia-only scenario reduced
the net benefit of the intervention compared with equiva-
lent analyses that did not include dementia. While the
indirect treatment effects via diabetes and stroke
increased cost savings, this effect was canceled out by
increased health care costs in additional years gained.
Including dementia as an outcome did not substantially
affect the incremental QALYs in this population, sug-
gesting that there are marginal QALY gains from
delayed onset of dementia and additional life years
gained in this context.
Guidelines for the development of cost-effectiveness
analyses for public health interventions recommend that
disease outcomes that do not affect the cost-effectiveness
outcomes can be excluded from model structures.29 In
this study, including dementia did not alter the recom-
mendations for the intervention or substantially affect
the health economic outcomes. As such, these analyses
did not provide a compelling argument to routinely
include dementia in public health models for lifestyle
interventions. One-way sensitivity analyses indicate that
the net benefit was not affected by changes to the natural
history of dementia, costs, or utilities, so this finding is
likely to be similar in other health care settings.
Nevertheless, the analyses have highlighted some situa-
tions where the inclusion of dementia may be influential.
The model was sensitive to the inclusion of a direct
intervention effect on dementia incidence. The reduced
dementia risk scenario and parameter sensitivity analyses
indicated that there were substantial cost savings and
QALY gains from reducing the incidence of dementia.
Therefore, inclusion of dementia as an outcome would be
justified for interventions with large and long-lasting
effects on modifiable risk factors that are included in the
CAIDE score, including education and physical activity.
These intervention effects were not included in this exam-
ple. Also, the direct intervention effects had the greatest
impact in older populations. Reducing dementia risk in
older populations was more valuable in this model, where
discount rates reduced cost and QALY gains in younger
populations whose major events occur further into the
future.
Conversely, in the dementia-only scenario, there is a
modest risk that the cost savings and QALY gains would
be overstated if dementia were not included in the model.
This impact is greatest in younger populations and those
at low risk of diabetes. Dementia moderated the health
economic outcomes of public health interventions, par-
ticularly where individuals were at a lower risk of health
complications and the health gains were accrued later in
life. This may be because younger populations will bene-
fit less from the indirect effects of reduced dementia
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incidence through reduced stroke and diabetes. This
finding is most likely to affect health economic evalua-
tions of population-wide, upstream interventions rather
than interventions targeting at smaller at-risk groups.
Few studies have included the costs of dementia in an
economic evaluation of lifestyle interventions targeting
diabetes and cardiovascular disease. Two studies focus-
ing on interventions to increase physical activity included
dementia as a health outcome.30,31 Increased physical
activity increased life expectancy and resulted in decreased
spending overall on health and social care, even after
accounting for additional spending during life years
gained. Both studies assumed a direct relationship between
physical activity and dementia, indicating health gains/cost
savings from reduced dementia incidence.
Public health interventions often affect multiple risk
factors and multiple disease outcomes. This is the first
economic evaluation to conduct a comprehensive evalua-
tion of the effects of a public health intervention by cap-
turing the health gains and costs across diabetes,
cardiovascular disease, cancer, osteoarthritis, dementia, and
depression.32 We have demonstrated that the additional
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burden of diseases, such as dementia in later life, does not
substantially affect the cost-effectiveness of a large-scale
public health intervention like the NHS DPP. This finding
will help guide the process of conceptualizing and deciding
the model boundary for future noncommunicable disease
models.
A key consideration when including dementia in a
model for public health interventions is how much detail
on dementia progression is necessary. In this model, we
allow for variability in disease severity at diagnosis, het-
erogeneity in MMSE score progression, and variation in
costs and HRQoL decrements across disease progression
states. This framework is more complex than previous
public health dementia models that specify dementia as
a single disease state. However, our approach is less
complex than cost-effectiveness models developed for
Alzheimer disease treatments, where domains for func-
tion and behavior are used to capture the broad nature
of Alzheimer disease and the benefits from treatment.
Including severity scales for behavioral and functional
abilities such as the Neuropsychiatric Inventory (NPI),
activities of daily living (ADLs), and instrumental ADLs
(IADL) would provide a more comprehensive descrip-
tion of dementia and a broader range of outcomes.
Getsios et al.21 estimated disease progression scores incor-
porating correlation between these measures. There is
no evidence from DPP trials to suggest that the inter-
vention affects behavioral and functional abilities, and
there is limited evidence on the impact of these factors
on costs and mortality. Excluding these measures is
unlikely to affect this evaluation. The complexity of
dementia progression must be weighed against the com-
putational burden of a multidisease microsimulation as
it is not feasible to model all diseases to the same stan-
dard as single-disease models. The MMSE domain pro-
gression structure allows the model to capture the most
important impacts of the timing of dementia onset
through deterioration in QALYs and increases in costs
over time. However, this modeling framework is not suf-
ficient to evaluate the benefits of treatment postdiagno-
sis or preventative interventions that affect patient
functioning at baseline.
The study is limited by the data available to describe
the effectiveness of the diabetes/CVD intervention in
reducing dementia incidence. In these analyses, we
assume that the maintenance of changes in metabolic
risk factor reduction is 5 years, and in the reduced
dementia risk model, risk of dementia is reduced for 20
years. There is considerable uncertainty in whether
short-term changes in risk factors can modify the risk of
dementia and how this relationship varies by age,
duration, and magnitude of change. We have based our
assumptions on data from an influential observational
study.4 However, 3 large multidomain trials (FINGER,
MAPT, and PreDIVA) have been completed in recent
years. The FINGER trial showed that a multidomain
lifestyle intervention can provide a marginal benefit for
cognition over a nonactive intervention in elderly people
with an elevated risk of dementia.33 The primary results
from the other trials did not show a statistically signifi-
cant benefit of preventive interventions,6,7 although sub-
group analyses of untreated hypertension showed
potential beneficial effects of intervention on dementia
incidence.7 Overall, results from these 3 trials suggest
that targeting of preventive interventions to at-risk indi-
viduals is an effective strategy, if limited in impact.
However, there is a need for more evidence from rando-
mized controlled trials to demonstrate whether modifica-
tions to metabolic risk factors result in reductions in
dementia incidence.
There is also considerable uncertainty in the relation-
ships between lifestyle interventions and dementia, and
careful consideration was given to characterizing treat-
ment benefit in the reduced dementia risk scenario.
However, the study was limited by evidence to describe
the characteristics of the treatment effect. The dementia-
only and reduced dementia risk scenarios demonstrate
the impact of dementia risk assumptions, from an indi-
rect effect from stroke and diabetes to an immediate risk
reduction for 20 years, on cost-effectiveness outcomes.
These scenarios provide an explicit range of cost-
effectiveness results, and the sensitivity analysis high-
lights the importance of the risk reduction parameter to
the net benefit. Within this boundary, the true effect may
be characterized by time lags, effects conditional on age
or deterioration in effect over time. However, modifica-
tions to these assumptions without a better understand-
ing of the mechanisms between lifestyle and dementia
risk would be arbitrary. There is a paucity of data on the
effect of changes in metabolic risk factors on the inci-
dence of dementia, and further research is needed to
explore the relationships between lifestyle and dementia
risk across the life course.
Conclusions
The study demonstrates that it is feasible to include
dementia as an outcome in public health modeling stud-
ies of lifestyle interventions. The study provides a frame-
work to model dementia alongside diabetes and
cardiovascular diseases. The inclusion of outcomes for
dementia moderates the cost savings associated with the
10 Medical Decision Making 00(0)
NHS DPP. However, there are gains in cost savings and
QALYs if the intervention directly reduces the incidence
of dementia. The addition of dementia in our model did
not alter the recommendation that the NHS DPP is a
cost-effective use of resources.
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